Discussing the Zoster Vaccine: An Interview with Julie Gerberding, President of Merck Vaccines

ArticleinPopulation Health Management 15(6) · October 2012with4 Reads
Impact Factor: 1.51 · DOI: 10.1089/pop.2012.1561 · Source: PubMed